The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Authors
Keywords
-
Journal
Diabetes Therapy
Volume 12, Issue 5, Pages 1523-1534
Publisher
Springer Science and Business Media LLC
Online
2021-04-15
DOI
10.1007/s13300-021-01040-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes
- (2020) Mafalda Ramos et al. Journal of Comparative Effectiveness Research
- Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review
- (2019) Michael Willis et al. Diabetes Therapy
- Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States
- (2019) Barnaby Hunt et al. ADVANCES IN THERAPY
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality
- (2018) Ronen Arbel et al. AMERICAN JOURNAL OF CARDIOLOGY
- The Cost of Diabetes Care—An Elephant in the Room
- (2018) Matthew C. Riddle et al. DIABETES CARE
- Economic Costs of Diabetes in the U.S. in 2017
- (2018) DIABETES CARE
- Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
- (2018) Wedad Rahman et al. EXPERT OPINION ON PHARMACOTHERAPY
- PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS
- (2018) C. Balijepalli et al. VALUE IN HEALTH
- The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
- (2017) Christian Bommer et al. Lancet Diabetes & Endocrinology
- Current perspectives on cardiovascular outcome trials in diabetes
- (2016) Oliver Schnell et al. Cardiovascular Diabetology
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Societal costs of diabetes mellitus in Denmark
- (2015) C. Sortsø et al. DIABETIC MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
- (2014) Bernard Zinman et al. Cardiovascular Diabetology
- Validation of the IMS CORE Diabetes Model
- (2014) Phil McEwan et al. VALUE IN HEALTH
- Review of Utility Values for Economic Modeling in Type 2 Diabetes
- (2014) Amélie Beaudet et al. VALUE IN HEALTH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now